PMV Pharmaceuticals Inc (PMVP) News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as...

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid...

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer

Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily...

Form 8-K - Current report

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a...

PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference

PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report